CANCER MECHANISMS RESEARCH PROGRAM

癌症机制计划（CM）的使命是促进跨学科合作， 加速基因发现和基因型信息之间的翻译连续体沿着进展 分子治疗CM在达特茅斯医学院组织以癌症为重点的基础科学， 达特茅斯学院和达特茅斯-希区柯克医学中心校区。CM研究人员有共同的 对癌基因和抑癌基因的正常功能的解剖感兴趣; 细胞周期和细胞凋亡;血管生成和转移的调节剂;以及干细胞和血液形成。的 CM计划通过引导努力实现三个转化目标来增加价值：分子疾病 分类;药物靶点和先导化合物鉴定;以及了解 小分子和基因型在癌症发生和治疗中的作用。通过促进基础设施之间的合作， 和来自10个部门的临床科学家，25名成员的计划已经创造了进步， 调查员可能做的。CM研究人员以当前年度总成本进行研究项目 资助1，290万美元（NCI提供290万美元）。项目成员在此期间发表了150多篇论文 延长期，其中15%来自方案内，44%来自方案间 合作。 CM还在建立和参与全面的乳房，肺， 胃肠道和神经肿瘤学项目，从而将基础科学家与人口科学家联合起来， 临床医生促进双向转化研究。CM科学家还组织了区域和国家 血液恶性肿瘤，肺癌和干细胞会议，其中富有成效的合作 形成了。展望未来，CM将利用新的肺癌小鼠模型等进展， 评价致癌作用的抑制剂，抗白血病融合蛋白的新靶向先导化合物， 和一种新发现的天然产物，可以防止化疗引起的神经变性， 从而将CM的发现转化为降低癌症发病率、癌症死亡率以及疼痛和痛苦的方法， 与癌症治疗有关。

The mission of the Cancer Mechanisms Program (CM) is to foster interdisciplinary collaborations and accelerate progress along the translational continuum between gene discovery and genotype-informed molecular treatments. CM organizes cancer-focused basic science on the Dartmouth Medical School, Dartmouth College, and Dartmouth-Hitchcock Medical Center campuses. CM investigators have common interests in dissecting the normal functions of oncogenes and tumor suppressor genes; regulators of cell cycle and apoptosis; regulators of angiogenesis and metastasis; and stem cells and blood formation. The CM Program adds value by channeling efforts toward three translational aims: molecular disease classification; drug target and lead compound identification; and understanding the complex interactions of small molecules and genotypes in carcinogenesis and treatment. By promoting collaborations among basic and clinical scientists from 10 departments, the 25-member Program has created advances that no single investigator could have made. CM investigators conduct research projects with a current annual total cost funding of $12.9 million ($2.9 million from NCI). Program members published more than 150 papers during the renewal period, of which 15% derived from intra-programmatic and 44% from inter-programmatic collaborations. CM has also assumed a leadership role in establishing and participating in comprehensive breast, lung, gastro-intestinal and neuro-oncology programs, thus uniting basic scientists with population scientists and clinicians to promote bidirectional translational research. CM scientists also organized regional and national meetings in hematological malignancies, lung cancer, and stem cells, out of which productive collaborations were formed. Going forward, CM will exploit advances such as a new mouse model for lung cancer to evaluate inhibitors of carcinogenesis, new targeted lead compounds against leukemogenic fusion proteins, and a newly discovered natural product that protects against chemotherapy-induced neurodegeneration, thereby translating CM discoveries to reduce cancer incidence, cancer death, and the pain and suffering associated with cancer treatment.